dc.contributor.author | Cheong, JL-Y | en_US |
dc.contributor.author | Goh, ZHK | en_US |
dc.contributor.author | Marras, C | en_US |
dc.contributor.author | Tanner, CM | en_US |
dc.contributor.author | Kasten, M | en_US |
dc.contributor.author | Noyce, AJ | en_US |
dc.contributor.author | Movement Disorders Society Epidemiology Study Group | en_US |
dc.date.accessioned | 2020-09-08T11:22:34Z | |
dc.date.available | 2020-08-23 | en_US |
dc.date.issued | 2020-08-28 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/66849 | |
dc.description.abstract | BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Mov Disord | en_US |
dc.subject | Parkinson's disease; COVID-19; epidemiology; access; medication | en_US |
dc.title | The Impact of COVID-19 on Access to Parkinson's Disease Medication. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1002/mds.28293 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32860226 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
dcterms.dateAccepted | 2020-08-23 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |